Nootropics & cognitive
PE 22-28
Engineered spadin analog with improved TREK-1 channel inhibition and fast-acting antidepressant properties.
Research chemical Nootropics & cognitive
- Full name
- PE 22-28; shortened spadin analog
- Also known as
- mini-spadin
- Regulatory status
- Research chemical; investigational, not approved for human use
Origin
A shortened 7-amino-acid analog of spadin, itself derived from sortilin/NTSR3 receptor maturation, engineered by French researchers (CNRS) to improve metabolic stability and TREK-1 potency over the parent molecule. First described in 2017.
Mechanism
Blocks TREK-1, a two-pore-domain potassium channel implicated in depression. This increases serotonergic neuron firing in the dorsal raphe nucleus, producing rapid antidepressant effects, and stimulates hippocampal neurogenesis and synaptogenesis.
Research summary
Evidence
Shows better TREK-1 binding affinity and longer in-vivo action (23 hours vs spadin's 7 hours). Demonstrates antidepressant efficacy in mouse behavioral tests and neuroprotection in stroke and post-stroke-depression models. All evidence is preclinical; no human trials published.
Evidence tier: Research chemical — see the methodology note for how this is assessed.
Citations
Reported benefits
- antidepressant effect (rapid onset in animal models)
- neuroprotection in stroke models
- neurogenesis stimulation
Dosing protocols reported in the literature & community
These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.
| Route | Reported protocol |
|---|---|
| Intraperitoneal injection (research only) | Mouse models: 0.03-3 μg/kg; no human dosing established. |
Side effects
- no human data
- good tolerability at therapeutic doses in animal studies
Safety notes
Community & reddit notes (anecdotal — not clinical evidence)
Virtually no self-experimenter reports. Too obscure and research-only at present.
Related peptides
Mixing compatibility
Pulled from a community-charted mixing-compatibility reference (anecdotal, clinic-use, and community-reported signals) — not a safety guarantee. Verify independently before combining anything.